Cerebrospinal Fluid Analysis of Pericytic Mediators in Clinically Isolated Syndrome and Multiple Sclerosis: A Preliminary Study

Abstract

DOI: 10.26650/experimed.2018.434227

Objectives: In many studies, blood brain barrier has been shown to be compromised in multiple sclerosis patients. Pericytes play an active role in ensuring the continuity of the blood brain barrier along with a series of cells. In this study, the effect of pericytic dysfunction on the development of demyelinating plaques in patients with multiple sclerosis was investigated.

Material and Method: Concentrations of pericyte dysfunction mediators (PDGFbb, MMP9, TIMP3 and ADAM17) in cerebrospinal fluid of patients with clinically isolated syndrome (CIS), relapsing remitting multiple sclerosis (RRMS) and healthy control group were measured by ELISA and oligoclonal bands (OCB) were investigated. We aimed to determine whether the concentration of these mediators differed between groups and whether they correlated with lesion load, number of attacks, and EDSS scores.

Results: Concentrations of all four mediators were similar in patients with CIS and RRMS. However, both groups were found to be higher than the healthy group. In the CIS and RRMS groups, the levels of the mediators were not correlated with any parameters examined. However, the levels of PDGFbb (p=0.045), MMP9 (p=0.037), and TIMP3 (p=0.033) were higher in OCB positive patients than in those without OCB, whereas ADAM17 levels remained unchanged.

Conclusion: This study shows that pericytes may play a role in the pathogenesis of MS from early stages of the disease. The presence of higher levels in patients with OCB suggests that pericyte dysfunction may be associated with OCB formation.

Keywords

• clinically isolated syndrome,pericyte,cerebrospinal fluid,neuroinflammation,Multiple sclerosis

Klinik İzole Sendrom ve Multipl Skleroz Hastalarının Beyin Omurilik Sıvılarında Perisitik Mediatörlerin Analizi: Pilot Çalışma

Abstract

DOI: 10.26650/experimed.2018.434227

Amaç: Multipl skleroz’da kan beyin bariyerinin bozulduğu pek çok çalışmada gösterilmiştir. Perisitler bir dizi hücre yanında kan beyin bariyerinin devamlılığının sağlanmasında aktif rol üstlenir. Bu çalışmada multipl skleroz hastalarında perisit disfonksiyonunun demyelinizan plakların gelişimindeki etkisi araştırılmıştır.

Gereç ve Yöntem: Klinik izole sendrom (KİS), relapsing remitting multipl skleroz (RRMS) ve sağlıklı kontrol grubundan alınan beyin omurilik sıvılarında perisit disfonksiyon mediatörlerinin (PDGFbb, MMP9, TIMP3 ve ADAM17) konsantrasyonları ELISA ile ölçüldü ve oligoklonal bantlar (OKB) araştırıldı. Bu mediyatörlerin, gruplar arasındaki farklılıkları lezyon yükü, atak sayısı ve EDSS skorları ile korelasyon gösterip göstermediği belirlendi.

Bulgular: Her dört mediyatörün konsantrasyonları KİS ve RRMS hastalarında benzer bulundu. Bununla beraber her iki grupta sağlıklı kontollerden yüksek bulundu. KİS ve RRMS grubunda, mediyatörlerin seviyelerinin bakılan hiçbir parametre ile korelasyon göstermediği saptandı. Buna karşın, beyin omurilik sıvılarında OKB bulunan hastalarda PDGFbb (p=0,045), MMP9 (p=0,037) ve TIMP3 (p=0,033) düzeylerinin OKB bulunmayanlara göre daha yüksek olduğu, ADAM17 seviyelerinin ise değişmediği görüldü.

Sonuç: Bu çalışma perisit disfonksiyon mediyatörlerinin MS’in patogenezinde hastalığın erken dönemlerinden itibaren rol alabileceğini göstermektedir. Oligoklonal band bulunan hastalarda daha yüksek seviyelerdeki mevcudiyeti, perisit disfonksiyonunun OKB oluşumu ile bir ilgisi olabileceğini akla getirmektedir.

Keywords

• klinik izole sendrom,perisit,beyin omurilik sıvısı,nöroinflamasyon,Multipl skleroz,nöroinflamasyon

References

1. Minagar A, Alexander JS. Blood-brain barrier disruption in multiple sclerosis. Mult Scler 2003;9:540-549.
2. Hill J, Rom S, Ramirez SH, Persidsky Y. Emerging roles of pericytes in the regulation of the neurovascular unit in health and disease. J Neuroimmune Pharmacol 2014;9:591-605.
3. Niu F, Yao H, Liao K, Buch S. HIV Tat 101-mediated loss of pericytes at the blood-brain barrier involves PDGF-BB. Ther Targets Neurol Dis 2015;2.
4. Shukla V, Shakya AK, Shukla M, Kumari N, Krishnani N, Dhole TN, Misra UK. Circulating levels of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases during Japanese encephalitis virus infection. Virusdisease 2016;27:63-76.
5. Candelario-Jalil E, Yang Y, Rosenberg GA. Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience 2009;158:983-994.
6. Muramatsu R, Kuroda M, Matoba K, Lin H, Takahashi C, Koyama Y, Yamashita T. Prostacyclin prevents pericyte loss and demyelination induced by lysophosphatidylcholine in the central nervous system. The Journal of biological chemistry 2015;290:11515-11525.
7. Fainardi E, Castellazzi M, Bellini T, Manfrinato MC, Baldi E, Casetta I, Paolino E, Granieri E, Dallocchio F. Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis. Mult Scler 2006;12:294-301.
8. Gold SM, Chalifoux S, Giesser BS, Voskuhl RR. Immune modulation and increased neurotrophic factor production in multiple sclerosis patients treated with testosterone. Journal of neuroinflammation 2008;5:32.

9. Haddock G, Cross AK, Plumb J, Surr J, Buttle DJ, Bunning RA, Woodroofe MN. Expression of ADAMTS-1, -4, -5 and TIMP-3 in normal and multiple sclerosis CNS white matter. Mult Scler 2006;12:386-396.
10. Ljubisavljevic S, Stojanovic I, Basic J, Vojinovic S, Stojanov D, Djordjevic G, Pavlovic D. The Role of Matrix Metalloproteinase 3 and 9 in the Pathogenesis of Acute Neuroinflammation. Implications for Disease Modifying Therapy. J Mol Neurosci 2015;56:840-847.
11. Farina G, Magliozzi R, Pitteri M, Reynolds R, Rossi S, Gajofatto A, Benedetti MD, Facchiano F, Monaco S, Calabrese M. Increased cortical lesion load and intrathecal inflammation is associated with oligoclonal bands in multiple sclerosis patients: a combined CSF and MRI study. Journal of neuroinflammation 2017;14:40.